• Je něco špatně v tomto záznamu ?

Burden of advanced breast cancer for patients and caregivers in Europe: comparison of two treatment forms of vinorelbine, oral and intravenous

S. Barni, B. Freier, I. Garau, JL. Mouysset, M. Sediva, C. Zamagni, G. Berdeaux, C. de Almeida Agudo,

. 2016 ; 32 (11) : 1807-1812. [pub] 20160722

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17031380

AIM: To assess the burden of disease associated with advanced breast cancer (ABC) treated with oral (VinO) or intravenous vinorelbine (VinIV) from the perspective of patients and caregivers in five European countries. METHODS: This was an observational, prospective, international, multicenter study. Patients were included in the study at the beginning of their second cycle of chemotherapy with vinorelbine and categorized into two groups depending on whether they received VinO or VinIV. At baseline (V0) and at the end of the second cycle of chemotherapy (V1), patients and caregivers were asked to complete self-administered questionnaires: SF-12 and burden of disease. RESULTS: At baseline, the two groups were well balanced in demographic and clinical characteristics. However, while HER2+ (human epidermal growth factor receptor 2) disease was significantly more frequent in patients receiving VinIV, patients receiving VinO were predominantly treated with single-agent therapy and were older than those treated with VinIV (67.1 years versus 57.7 years [p = 0.05]). As measured with SF-12, patients with VinO had, at end of cycle 1 and end of cycle 2, significantly more favorable outcomes in physical summary score, role physical, role emotional and mental health (all p < 0.05) than those treated with VinIV. Trends for a better caregiver mental score and social functioning were also observed with VinO (cycle 1 and 2; p < 0.10). From a patient perspective, no major difference was reported on the burden of disease between the two groups, however, a trend for a better" overall impact on daily life" was observed in VinO patients. Major significant differences, showing a lower burden of disease with VinO, were also reported from caregivers. In addition, in patients treated with VinO, mental score was almost similar to the one of the general population. CONCLUSION: VinO showed benefits over VinIV for both patients and caregivers, particularly in health related quality of life and burden of disease. Because of its observational design, results are only informative.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031380
003      
CZ-PrNML
005      
20171031101114.0
007      
ta
008      
171025s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/03007995.2016.1211518 $2 doi
035    __
$a (PubMed)27388853
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Barni, Sandro $u a ASST Bergamo Ovest Ospedale di Treviglio , Italy.
245    10
$a Burden of advanced breast cancer for patients and caregivers in Europe: comparison of two treatment forms of vinorelbine, oral and intravenous / $c S. Barni, B. Freier, I. Garau, JL. Mouysset, M. Sediva, C. Zamagni, G. Berdeaux, C. de Almeida Agudo,
520    9_
$a AIM: To assess the burden of disease associated with advanced breast cancer (ABC) treated with oral (VinO) or intravenous vinorelbine (VinIV) from the perspective of patients and caregivers in five European countries. METHODS: This was an observational, prospective, international, multicenter study. Patients were included in the study at the beginning of their second cycle of chemotherapy with vinorelbine and categorized into two groups depending on whether they received VinO or VinIV. At baseline (V0) and at the end of the second cycle of chemotherapy (V1), patients and caregivers were asked to complete self-administered questionnaires: SF-12 and burden of disease. RESULTS: At baseline, the two groups were well balanced in demographic and clinical characteristics. However, while HER2+ (human epidermal growth factor receptor 2) disease was significantly more frequent in patients receiving VinIV, patients receiving VinO were predominantly treated with single-agent therapy and were older than those treated with VinIV (67.1 years versus 57.7 years [p = 0.05]). As measured with SF-12, patients with VinO had, at end of cycle 1 and end of cycle 2, significantly more favorable outcomes in physical summary score, role physical, role emotional and mental health (all p < 0.05) than those treated with VinIV. Trends for a better caregiver mental score and social functioning were also observed with VinO (cycle 1 and 2; p < 0.10). From a patient perspective, no major difference was reported on the burden of disease between the two groups, however, a trend for a better" overall impact on daily life" was observed in VinO patients. Major significant differences, showing a lower burden of disease with VinO, were also reported from caregivers. In addition, in patients treated with VinO, mental score was almost similar to the one of the general population. CONCLUSION: VinO showed benefits over VinIV for both patients and caregivers, particularly in health related quality of life and burden of disease. Because of its observational design, results are only informative.
650    _2
$a aplikace orální $7 D000284
650    _2
$a senioři $7 D000368
650    _2
$a nádory prsu $x farmakoterapie $x psychologie $7 D001943
650    12
$a osoby pečující o pacienty $7 D017028
650    _2
$a osobní újma zaviněná nemocí $7 D017281
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a intravenózní infuze $7 D007262
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a kvalita života $7 D011788
650    _2
$a vinblastin $x aplikace a dávkování $x analogy a deriváty $7 D014747
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Freier, Beata $u b Uniwersytecki Szpital Kliniczny , Wroclaw , Poland.
700    1_
$a Garau, Isabel $u c Son Llatzer , Palma de Mallorca , Spain.
700    1_
$a Mouysset, Jean-Loup $u d Clinique Provençale , Aix en Provence , France.
700    1_
$a Sediva, Marcela $u e Bulovka University Hospital , Prague , Czech Republic.
700    1_
$a Zamagni, Claudio $u f Oncologia Medica Addarii Policlinico S. Orsola Malpighi , Bologna , Italy.
700    1_
$a Berdeaux, Gilles $u g Pierre Fabre SA , Boulogne-Billancourt , France.
700    1_
$a de Almeida Agudo, Cecilia $u h Pierre Fabre Médicament , Boulogne-Billancourt , France.
773    0_
$w MED00009520 $t Current medical research and opinion $x 1473-4877 $g Roč. 32, č. 11 (2016), s. 1807-1812
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27388853 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171031101204 $b ABA008
999    __
$a ok $b bmc $g 1254973 $s 992407
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 32 $c 11 $d 1807-1812 $e 20160722 $i 1473-4877 $m Current medical research and opinion $n Curr Med Res Opin $x MED00009520
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace